Results 161 to 170 of about 208,148 (266)

Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.

Haematologica, 2000
Although bcr-abl polymerase chain reaction (PCR) positivity after bone marrow transplantation (BMT) for chronic myelogenous leukemia (CML) is significantly related to relapse, the predictive value of the assay is not very high and therefore most investigators consider that qualitative RT-PCR data alone are too imprecise to enable clinical decisions to ...
J, Román, J, Serrano, A, Jiménez, J A, Castillejo, M L, Reina, M G, González, M C, Rodríguez, I, García, J, Sánchez, J, Maldonado, A, Torres   +10 more
openaire   +1 more source

Reverse Degree-Based Topological Indices and QSPR Analysis of Cancer Drugs [PDF]

arXiv
A topological index of a graph $G$ is a numerical quantity that describes its topology. Reverse degree-based topological indices play an important role in finding topological descriptors. Azacitidine, Decitabine, and Guadecitabine are hypomethylating agents which are used for the treatment of patients with higher-risk myelodysplastic syndromes, acute ...
arxiv  

Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.

Folia biologica, 2001
Several groups have shown that Ph-progenitors reappear in LTC of CML bone marrow or PBMNC when the cell preparations were derived from newly diagnosed Ph-positive patients or after induction chemotherapy. We have tested the hypothesis whether LTC may further decrease CML progenitors if the cells to be cultured were from IFN-treated patients.
B, Schultheis, B, Heissig, G, Pasternak, S, Hörner, R, Hehlmann   +4 more
openaire   +1 more source

ULV: A robust statistical method for clustered data, with applications to multisubject, single-cell omics data [PDF]

arXiv
Molecular and genomic technological advancements have greatly enhanced our understanding of biological processes by allowing us to quantify key biological variables such as gene expression, protein levels, and microbiome compositions. These breakthroughs have enabled us to achieve increasingly higher levels of resolution in our measurements ...
arxiv  

New onset diabetes manifesting as diabetic ketoacidosis in a patient with chronic myelogenous leukemia treated with imatinib. [PDF]

Arch Endocrinol Metab
Salimova D, Aloyan T, Qureshi U, Qureshi F, Wazir H.   +4 more
europepmc   +1 more source

Treatment of <i>JAK2</i> V617F-positive primary myelofibrosis and advanced chronic myelogenous leukemia with ruxolitinib and flumatinib: a case report. [PDF]

Ann Med Surg (Lond)
Zhu F, Wang H, Qiu L.
europepmc   +1 more source

The road not taken: Exploring non-transplant options in De Novo philadelphia positive acute myeloid leukemia. [PDF]

Leuk Res Rep
Sharif MI, Alotaibi AS, Alyamany R, Alahmari A, Alkhaldi H, Saad A, Alfayez M.   +6 more
europepmc   +1 more source

Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 BCR::ABL1 fusion transcripts: a case report and review of the literature. [PDF]

Front Oncol
Xu Y, Fan Y, Liu S, Chang J, Guo C, Chen L, Guo W, Dang J, Wang H, Tan Y.   +9 more
europepmc   +1 more source

Cardiac arrhythmias of BCR-ABL inhibitors with or without triazole antifungal agents: A real-world pharmacovigilance study based on the food and drug administration adverse event reporting system database. [PDF]

SAGE Open Med
Xie P, Lu L, Tian Y, Jia R, Tian X, Bai P.   +5 more
europepmc   +1 more source

Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. [PDF]

Mediterr J Hematol Infect Dis
Paciaroni K, Campagna S, Villiva N, Maffini E, Celesti F, Tordi A, Lombardi M, Dragonetti G, di Toritto TC.   +8 more
europepmc   +1 more source